Endocrine Society Launches Rare Endocrine Disease Fellows Program

The Endocrine Society is pleased to announce its Rare Endocrine Disease (RED) Fellows Program, a series designed to equip early-career physicians with the knowledge and practical skills needed to improve outcomes for people living with rare endocrine diseases.

The program was developed in partnership with the National Organization for Rare Disorders (NORD) and addresses critical gaps in awareness, diagnosis and care of rare endocrine diseases.

The program consists of two core components:

  • An immersive in-person workshop held April 17-18 at the Endocrine Society Headquarters in downtown Washington, D.C., where fellows can engage directly with leading experts in rare endocrine diseases, participate in interactive, case-based discussions, and gain access to the NORD rare patient panel; and
  • Five on-demand, multi-module courses featuring short micro-lessons covering individual rare endocrine diseases. 

The program accepts up to 50 domestic fellows, and the deadline for program directors and other faculty to nominate a fellow is March 2, 2026.

For more details on the program, including eligibility, learning objectives and the program agenda, visit: endocrine.org/education-and-training/rare-endocrine-disease-fellows-series.

This program is supported by educational grants from Alexion Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., BridgeBio Pharma, Inc., Chiesi USA, Inc., Corcept Therapeutics, Inc., and Crinetics Pharmaceuticals, Inc.

You may also like

  • Endocrine Society Endorses Bipartisan Bill to Address Insulin Affordability 

    INSULIN Act would expand insulin co-pay cap to commercial market and encourage competition. The Endocrine Society today endorsed the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, a bipartisan bill to address insulin affordability introduced by Sens. Jeanne Shaheen (D-NH), Susan Collins (R-ME), Raphael Warnock (D-GA), and John Kennedy (R-LA).   This historic legislation would cap out-of-pocket insulin costs at $35 per month for people on private insurance, protecting access to this life-saving medication for millions of people with diabetes. The legislation also would create a program to…

  • In Memoriam: Martin Savage 1941-2026

    Martin O. Savage, Emeritus Professor of Pediatric Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, passed away on February 24, 2026. Martin Savage was a kind, generous, quietly spoken man, an inspirational pediatrician and an internationally renowned clinician scientist. He was passionate about teaching…

Find more in